EKF Diagnostics Investor Announcements

Final results for the year ended 31 December 2012.

EKF Diagnostics announces that it has established a new subsidiary, EKF Molecular Diagnostics Limited (“EKF Molecular”), to focus on molecular and companion diagnostics.

EKF announces 2012 Interim Results.

EKF Diagnostics announces that subsidiaries of EKF have entered into a Settlement Agreement with HemoCue AB and HemoCue Inc in relation to patent-related litigation in Germany and the US. 

EKF Diagnostics announces that it has signed an exclusive license agreement with the Joslin Diabetes Center (“Joslin”).

EKF Diagnostics announces that it has sold its Swiss subsidiary, International Brand Licensing AG for a cash consideration of £50,000, payable over a two year period. 

EKF Diagnostics announces its audited final results for the year ended 31 December 2011, a year of continued progress.

EKF Diagnostics has been awarded a contract in Mexico for 3,500 HemoPoint H2 haemoglobin testing devices.

EKF Diagnostics Holdings plc announces its unaudited interim results for the six month period ended 30 June 2011, a period of transition, investment and progression.

EKF Diagnostics announces that it has entered into a conditional distribution agreement with Alere Inc.